Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora

S M Finegold; D Molitoris; M-L Väisänen

doi:10.1128/AAC.00441-08

Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora

Antimicrob Agents Chemother. 2009 Jan;53(1):281-6. doi: 10.1128/AAC.00441-08. Epub 2008 Oct 27.

Authors

S M Finegold¹, D Molitoris, M-L Väisänen

Affiliation

¹ Department of Medicine, Medical and Research Services, VA Greater Los Angeles Healthcare System, UCLA School of Medicine, Los Angeles, California 90073, USA. sidfinegol@aol.com

Abstract

Rifaximin, ampicillin-sulbactam, neomycin, nitazoxanide, teicoplanin, and vancomycin were tested against 536 strains of anaerobic bacteria. The overall MIC of rifaximin at which 50% of strains were inhibited was 0.25 microg/ml. Ninety percent of the strains tested were inhibited by 256 microg/ml of rifaximin or less, an activity equivalent to those of teicoplanin and vancomycin but less than those of nitazoxanide and ampicillin-sulbactam.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Ampicillin / pharmacology
Bacteria, Anaerobic / drug effects*
Feces / microbiology*
Microbial Sensitivity Tests
Neomycin / pharmacology
Nitro Compounds
Rifamycins / pharmacology*
Rifaximin
Sulbactam / pharmacology
Teicoplanin / pharmacology
Thiazoles / pharmacology
Vancomycin / pharmacology

Substances

Nitro Compounds
Rifamycins
Thiazoles
Teicoplanin
Vancomycin
Ampicillin
Neomycin
Rifaximin
Sulbactam
nitazoxanide